TVTX

SEC source: 0001209191-23-048255 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 247,050

F1 · kind: On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.

SEC source: 0001209191-23-030959 · doc4.xml · derivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030959 · doc4.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,500

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030956 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030956 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,375

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030950 · doc4.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030950 · doc4.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,375

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030967 · doc4.xml · derivative · entry 2

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030967 · doc4.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,500

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030965 · doc4.xml · derivative · entry 2

Poole Sandra · CIK 0001619622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030965 · doc4.xml · nonDerivative · entry 1

Poole Sandra · CIK 0001619622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030958 · doc4.xml · derivative · entry 2

COUGHLIN TIMOTHY · CIK 0001376043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030958 · doc4.xml · nonDerivative · entry 1

COUGHLIN TIMOTHY · CIK 0001376043 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,500

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030963 · doc4.xml · derivative · entry 2

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030963 · doc4.xml · nonDerivative · entry 1

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,750

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030961 · doc4.xml · derivative · entry 2

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030961 · doc4.xml · nonDerivative · entry 1

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,500

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-030949 · doc4.xml · derivative · entry 2

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030949 · doc4.xml · nonDerivative · entry 1

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,750

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,247

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on September 14, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,369

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-029023 · doc4.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,031

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-029012 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,611

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on November 23, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-029000 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,211

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on November 10, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-024205 · doc4.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,486

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,805

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,165

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-006436 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,436

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006432 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,036

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006425 · doc4.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,069

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-006422 · doc4.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,533

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-23-006417 · doc4.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,150

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006413 · doc4.xml · derivative · entry 4

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-01-30

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,836

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006420 · doc4.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F3 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F3 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006420 · doc4.xml · derivative · entry 2

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006420 · doc4.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,757

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006436 · doc4.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006436 · doc4.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006436 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,026

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006432 · doc4.xml · derivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006432 · doc4.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006432 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,626

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006425 · doc4.xml · derivative · entry 4

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006425 · doc4.xml · derivative · entry 3

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006425 · doc4.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,848

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006422 · doc4.xml · derivative · entry 4

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006422 · doc4.xml · derivative · entry 3

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006422 · doc4.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,121

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-006417 · doc4.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.